Henry James R, Li Yihong, Warshawsky Alan M, Brozinick Joseph T, Hawkins Eric D, Misener Elizabeth A, Briere Daniel A, Montrose-Rafizadeh Chahrzad, Zink Richard W, Yumibe Nathan P, Ajamie Rose T, Wilken Brad, Devanarayan Viswanath
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. doi: 10.1016/j.bmcl.2006.09.028. Epub 2006 Sep 26.
Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described.
新型四氢异喹啉已被开发为有效的过氧化物酶体增殖物激活受体(PPAR)配体。本文描述了在2型糖尿病的PPARγ反应模型中对这些化合物的评估。